Respiratory failure & ventilation
High-Dose Inhaled Nitric Oxide in Acute Hypoxemic Respiratory Failure Due to Coronavirus Disease (COVID-19): A Multicenter Phase II Trial
Primary resultResult — go to the resultMean difference 39.1 mmHg 95% CrI 18.1–60.3Authors' conclusion
The use of high-dose inhaled nitric oxide resulted in an improvement of PaO2/FiO2 at 48 hours compared with usual care in adults with acute hypoxemic respiratory failure due to COVID-19.
Study context
- Population
- Mechanically ventilated adults with COVID-19 pneumoniamodified ITT analysis
- Participants
- 193 participants
- Comparison
- Inhaled nitric oxide 80 ppm for 48 hours vs usual care
- Primary endpoint
- Change in arterial oxygenation (PaO2/FiO2)
- Follow-up
- 48 hours
Methodological detailsphase II, multicentre, single-blind, parallel-arm
- Phase II
- Multicentre
- Single-blind
- Parallel-arm
Primary result
As reported in the abstract
Mean difference
39.1 mmHg
95% CrI 18.1–60.3
By group
Inhaled nitric oxide vs Control
mean difference 39.1 mmHg (95% CrI 18.1–60.3)
Secondary outcomes
Time to reach target PaO2/FiO2 (sustained for at least 24 h) · CrI
mean difference 0.44 (23.63–4.53)
| Outcome | Inhaled nitric oxide | Control | RR (95% CrI) | |
|---|---|---|---|---|
| Proportion attaining target PaO2/FiO2 · 28 daysCrI | 27.7% | 17.2% | 2.03 (1.11–3.86) | |
| 0.20.5125Relative risk (log scale) |
Duration of ventilation and mortality at 28 and 90 days
- Did not differ
Safety
- No serious adverse events reported
Original publication
High-Dose Inhaled Nitric Oxide in Acute Hypoxemic Respiratory Failure Due to COVID-19: A Multicenter Phase II Trial. Am J Respir Crit Care Med. Published 15 December 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →